



21-1-2013

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai

Sub: Unaudited Financial Results for the Quarter ended 31st December, 2012

Dear Sir,

With reference to the captioned matter, we enclose herewith the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2012, duly reviewed by the statutory auditors of the Company and approved by Board of Directors of the Company at its meeting held today i.e. 21st January, 2013.

We also enclose herewith the press release dated 21st January, 2013

Please take note of the same.

Thanking you,
For Alembic Pharmaceuticals Limited


R. K. Baheti
Director-Finance
& Company Secretary

Encl.: A/a

ALEMBIC PHARMACEUTICALS LIMITED


REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280350, 2280880, • FAX : (0265) 2282808
www.alembic-india.com • E-mail : alembic@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodra 390 003
UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 31ST DECEMBER, 2012

Rs in Lacs

Particulars	CONSOLIDATED					
	Quarter Ended			Nine Months		Year Ended
	December-12	September-12	December-11	December-12	December-11	March-12
PART- I	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1 (a) Net Sales / Income from Operations						
Domestic	25,470	28,913	21,765	77,252	87,391	87,719
Exports	11,735	11,840	16,316	37,571	43,168	39,071
Total	37,205	40,753	38,082	114,824	112,339	146,789
Less : Excise Duty	328	173	149	897	403	654
Net Sales / Income from Operations	36,880	40,580	38,133	114,007	112,156	146,235
(b) Other Operating Income	48	103	79	223	222	404
Total Income from Operations	36,928	40,683	38,212	114,230	112,378	146,639
2 Expenses						
(a) Decrease/(increase) in stock in trade and work in progress	(2,223)	1,949	250	(418)	(3,009)	(6,444)
(b) Consumption of Raw Materials & Packing Materials	12,420	12,631	12,916	38,220	40,140	52,824
(c) Purchase of traded goods	4,888	4,277	5,774	13,558	16,357	24,412
(d) Employees' Cost	4,932	4,853	4,324	14,302	12,535	16,846
(e) Research and Development Expense	3,472	1,603	976	3,163	3,645	6,888
(f) Excise Duty	(303)	117	(37)	(71)	198	809
(g) Other Expenditure	6,103	8,783	7,161	24,868	22,582	20,393
Total Expenses	38,288	34,215	31,564	95,692	94,448	124,597
3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	8,640	6,470	6,648	18,538	17,930	22,041
4 Other Income	342	22	13	386	31	44
5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	7,282	6,492	6,661	18,924	17,961	22,085
6 Depreciation	883	882	809	2,633	2,473	3,362
7 Interest (Net)	388	312	698	1,274	2,083	2,821
8 Net Profit / (Loss) from Ordinary Activities before Tax	6,009	5,298	5,354	16,117	13,405	16,098
9 Tax Expense						
Less : Provision for Current Tax	1,211	1,088	964	2,997	2,597	3,123
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	(29)	(8)	(33)	(40)	(175)	(38)
10 Net Profit / (Loss) from Ordinary Activities after Tax	4,827	4,249	4,423	13,160	10,813	13,014
11 Paid up Equity Share Capital	3,770	3,770	3,770	3,770	3,770	3,770
(Face value of share * 2/-)						
12 Reserves excluding Revaluation Reserve	-	-	-	-	-	35,730
13 Debenture Redemption Reserve	-	-	-	-	-	3,125
14 Basic & Diluted EPS (Net Annualised)	2.56	2.23	2.33	6.43	5.83	6.90
PART- II						
A Particulars of Shareholding						
1 Public Shareholding						
- Number of Shares	48777294	48777294	48783089	48777294	48763089	48763089
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2 Promoters and Promoter Group Shareholding						
- Fully Non - Encumbered						
- Number of Shares	139738620	139738620	139738625	139738620	139752825	139752825
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS	Quarter ended on 31st December, 2012					
Pending at the beginning of the quarter	NIL					
Received during the quarter	1					
Disposed of during the quarter	1					
Remaining unresolved at the end of the quarter	NIL					






ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodra 390 002
UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 31ST DECEMBER, 2012

Rs. in Lacs

	Particulars	STANDALONE					
		Quarter Ended			Nine Months		Year Ended
		December-12	September-12	December-11	December-12	December-11	March-12
		(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
PART - I							
1	(a) Net Sales / Income from Operations						
	Domestic	38,490	28,813	21,705	77,383	87,381	87,718
	Exports	11,735	11,840	13,294	34,728	38,461	49,861
	Total	37,205	40,753	35,000	112,028	105,852	137,679
	Less : Excise Duty	328	171	149	697	401	884
	Net Sales / Income from Operations	26,880	40,580	34,851	111,331	105,449	137,125
	(b) Other Operating Income	48	105	79	222	222	484
	Total Income from Operations	26,928	40,685	34,930	111,553	105,671	137,609
2	Expenses						
	(a) Decrease/(Increase) in stock in trade and work in progress	(2,223)	1,040	230	(418)	(3,009)	(6,444)
	(b) Consumption of Raw Materials & Packing Materials	12,420	12,631	12,916	38,320	40,140	52,824
	(c) Purchase of traded goods	4,886	4,277	3,272	13,311	12,668	16,779
	(d) Employees' Cost	4,882	4,888	4,324	14,302	12,535	16,846
	(e) Research and Development Expense	2,172	1,603	976	5,153	3,648	8,858
	(f) Excise Duty	(302)	117	(37)	(71)	198	809
	(g) Other Expenditure	8,819	8,888	7,263	24,929	22,487	30,200
	Total Expenses	29,804	24,330	28,384	93,347	88,685	116,871
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	7,024	6,355	6,038	18,206	17,086	20,937
4	Other Income	242	22	13	388	31	44
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	7,266	6,377	6,039	18,594	17,027	21,001
6	Depreciation	889	882	889	2,632	2,473	3,268
7	Interest (Net)	388	312	698	1,374	2,083	2,621
8	Net Profit / (Loss) from Ordinary Activities before Tax	6,089	5,183	4,532	14,588	12,481	15,015
9	Tax Expense						
	Less : Provision for Current Tax	1,322	1,042	864	2,851	2,492	3,000
	Less /Add : Provision for Deferred Tax Liability/(Assets)	(29)	(6)	(33)	(40)	(176)	(38)
10	Net Profit / (Loss) from Ordinary Activities after Tax	4,900	4,147	3,701	11,777	10,184	12,024
11	Paid up Equity Share Capital (Face Value of share - 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve	-	-	-	-	-	32,316
13	Debt Redemption Reserve	-	-	-	-	-	9,125
14	Basic & Diluted EPS (Not Annualised)	2.80	2.20	1.96	6.25	5.39	6.39
PART - II							
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777394	48777294	48763089	48777394	48763089	48763089
	- Percentage of Shareholding	24.87	25.07	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139728620	139738620	139738625	139738620	139738625	139738625
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
INVESTOR COMPLAINTS							
Quarter ended on 31st December, 2012							
	Pending at the beginning of the quarter			NIL			
	Received during the quarter			1			
	Disposed of during the quarter			1			
	Remaining unreceived at the end of the quarter			NIL			



Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

Place : Vadodara
Date : 21st January 2013

For Alembic Pharmaceuticals Limited



Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com



K. S. AIYAR & CO
CHARTERED ACCOUNTANTS

P-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road, Vadodara.

**RE: LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 31st December, 2012.**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Alembic Pharmaceuticals Limited for the quarter ended on 31st December, 2012 and the consolidated year to-date results for the period from 01-04-2012 to 31-12-2012 attached herewith except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management and have not been audited by us. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this interim financial information based on our review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.
2. We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. We report that the consolidated unaudited financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard (AS) 21 - Consolidated Financial Statements issued by the Central Government of India pursuant to Companies (Accounting Standards) Rules, 2006 and on the basis of the separate unaudited financial results of the wholly owned subsidiary of the Company (i.e. Alembic Global Holdings SA, Switzerland) which have not been reviewed but are included in the said consolidated results. The unaudited financial results of the Subsidiary reflect Company's share in the Revenue of Rs. Nil for the quarter and Rs. 2736.46 Lacs for the nine months period ended on 31-12-2012 and in loss of Rs. 71.61 Lacs for the quarter and in Profit of Rs. 385.76 Lacs for the nine months period ended on 31-12-2012.


Offices also at
Chennai Kolkata Goa
Bhubaneswar Bangalore Coimbatore

K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W


Raghuvir M. Aiyar
Partner
M.No. 38128

Place: Vadodara
Date: 21-01-2013

For Immediate Release
Alembic Pharmaceuticals Ltd.
Consolidated Results for quarter ended 31.12.2012

PBT up 12% at Rs 60.09 crores against Rs. 53.54 crores in PY
EBITDA at 18.8% at Rs. 69.40 crores
6 ANDA filed in quarter. Total filing at 55

Editors Synopsis

Quarter ended 31st December, 2012

- **Net profit after tax up 9.1% for the quarter at Rs. 48.27 crores vis-à-vis Rs. 44.23 crores in P.Y.**
- **Profit before tax up 12.2% at 60.09 crores against Rs. 53.54 crores in corresponding quarter last year**
- **EBITDA at 18.8% at Rs. 69.40 crores for the quarter against 17.9% at Rs. 68.48 crores**
- **Domestic formulations sales up 15% for the quarter at Rs. 228 crores against Rs. 199 crores in corresponding quarter last year**
- **Net sales at Rs 372 crores for the quarter against Rs. 383 crores in corresponding quarter last year**
- **Six ANDA filing during the quarter. Cumulative filing of ANDA stands at 55. Cumulative approvals of ANDA at 21.**

Vadodara, 21th January, 2013

Alembic Pharmaceuticals Limited reported growth in net profit by 9.1% at Rs. 48.27 crores for the quarter ended 31st December 2012 against Rs. 44.23 crores in corresponding quarter last fiscal.

The Company posted 12.2% growth in profit before tax at Rs. 60.09 crores for the quarter ended 31st December 2012 against Rs 53.54 crores posted in corresponding quarter last fiscal.

The company posted total revenue of Rs 372.05 crores for the quarter ended 31st December 2012, compared to Rs 382.82 crores in the corresponding quarter last year.

Domestic Formulations Business

The Domestic formulations business posted sales of Rs. 227.64 crores against Rs. 198.78 crores with a 15% growth over the corresponding quarter of the previous year against the backdrop of slowing growth rate of IPM.

Alembic maintained market share of 1.76%.

Azithral was ranked 25th and Alembic has three other brands in the list of top 300 brands of Industry i.e. 'Althrocin', 'Roxid', and 'Wikoryl'.

Chronic and acute segments grew by 23% and 4% respectively in current year.

The company launched a dermatology division in current year

API

For the quarter, Domestic API sales were Rs. 24.99 crores against Rs. 18.73 crores while export API sales were Rs. 42.00 crores against Rs. 89.90 crores last year.

International Generics

International Generic Formulation sales is Rs. 61.05 crores against Rs. 58.45 crores over the corresponding quarter last year.

During the quarter 6 ANDA application was filed taking cumulative ANDA and NDA filings of the Company to 55. Cumulative ANDA approvals now stands at 21.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. In Lacs)

Particulars			
	Q3 FY13	Q3 FY12	% Change
Formulation			
Domestic	22764	19878	15%
International Branded	6105	5845	4%
International Generics	1503	1560	(-)4%
API			
Domestic	2499	1873	33%
International	4200	8990	(-)53%
Export Incentives	134	136	(-)1%
Total	37205	38282	(-)3%

The Profit break-up for the quarter is as under:

(Rs. In Lacs)

Particulars	Q3 FY13	Q3 FY12	% Change
Operating Income	6940	6848	1%
Profit Before Tax	6009	5354	12%
Net Profit after Tax	4827	4423	9%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3600 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more Information:

Mitanshu Shah

Phone: +91 265 - 3007630

Email: mitanshu.shah@alembic.co.in

Alembic Pharmaceuticals Limited